Purpose To investigate roxadustat’s preventive effects on hypoxia damage in the quick ascent to high altitude. Methods The roxadustat (7.8 mg/kg, 15.6 mg/kg, and 31.2 mg/kg) and control groups of BALB/C mice were distributed at random. To evaluate roxadustat’s anti-hypoxic effectiveness at the recommended dose, an atmospheric pressure closed hypoxic experiment was used. Wistar rats were randomly assigned to groups that received normal oxygen, hypoxic, acetazolamide, or roxadustat in order to evaluate the protective effects against hypoxic damage. Animal blood was obtained for arterial blood-gas analysis, inflammatory factors, and the identification of oxidative stress indicators. Animal tissues were removed for pathological investigation. Results In each group, the mice’s survival time was noticeably extended compared to the normal oxygen group. The medium dose had the best time extension rate at 19.05%. Blood SatO 2 and PaO 2 were significantly higher in the roxadustat group compared to the hypoxic group. Erythrocyte content, hemoglobin content, and hematocrit were also significantly higher. Plasma levels of IL-6, TNF-α, and IFN-γ were also significantly lower in the roxadustat group. Roxadustat can also improve the level of oxidative stress in the tissues of hypoxic rats. According to the results of HE staining, roxadustat could greatly lessen the harm done to rat heart, brain, lung, liver, and kidney tissue as a result of hypoxia. Conclusion Roxadustat can greatly reduce inflammation, oxidative stress, and tissue damage brought on by hypoxia, showing that it can significantly enhance the body’s ability to adapt to high altitude exposure.
Objectives: To explore the protective effects of roxadustat on hypoxia damage in the fast access to high altitude. Methods: BALB/C mice were randomly divided into control, roxadustat-7.8 mg/kg, roxadustat-15.6 mg/kg and roxadustat-31.2 mg/kg groups. The anti-hypoxic effectiveness of roxadustat in an optimal dose was evaluated by atmospheric pressure closed hypoxic experiment. Wistar rats were randomly divided into normal pressure, hypoxia model, acetazolamide and roxadustat groups to evaluate the protective effects against hypoxic damage. Animal blood was collected for arterial blood-gas analysis, cytokines detection, oxidative stress indicators, and their organs were harvested for pathological examination. Results: Compared with the control group, the survival time of mice were significantly prolonged in all groups. The time prolongation rate of the medium dose was 19.05%, which was the best dose. Compared with the hypoxia model group, the blood SatO2 and PaO2 in the roxadustat group were significantly increased; Erythrocyte content, hemoglobin content and hematocrit were significantly increased; Plasma levels of IL-6, TNF-α and IFN-γ were significantly decreased; MDA content in the myocardial, brain, lung and liver tissue were significantly decreased, SOD activity and GSH content in the tissue were significantly increased. The results of HE staining indicated that roxadustat could significantly improve the damage of heart, brain, lung, liver and kidney tissue after hypoxia in rats. Conlusions: Roxadustat can significantly prevent hypoxia-induced tissue damage, oxidative stress and inflammatory response indicating that roxadustat can obviously improve the adaptation to high-altitude exposure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.